Management Team


BioCardia's management team gathers together industry veterans with a wealth of experience and a commitment to driving BioCardia forward as the leading developer of regenerative medicines for the treatment of cardiovascular disease.

Peter Altman, Ph.D. - President & CEO View profile
David McClung, CFO View profile
Edward Gillis - Sr. VP of Devices View profile
Phil Pesta - VP of Operations View profile
Ian McNiece, Ph.D. - CSO View profile
Debby Holmes-Higgin, MPH - VP, Clinical & Study Recruiting View profile
Sujith Shetty - VP, Clinical Operations & Regulatory View profile

News

04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More
08 Feb

Cell & Gene

Inside BioCardia's CardiAMP Cell Therapy
Read More
15 Sep

BioTuesdays

BioCardia developing autologous and allogenic cardiovascular cell therapies
Read More
03 Aug

Pharmaceutical Technology

BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
Read More
28 Jul

The Big Biz show

The Big Biz Show interviews BioCardia CEO, Peter Altman
Read More
10 Jan

HealthCare Weekly

5 Innovations That Will Change the Treatment of Heart Disease
Read More

press releases

30 Mar
2021 BioCardia Reports 2020 Financial Results and Recent Business Highlights
15 Mar
2021 BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
23 Feb
2021 BioCardia Signs Agreement with Leading Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates
17 Feb
2021 BioCardia Announces Clinical Leadership Changes
02 Feb
2021 BioCardia Update on Cell Therapy Product Development and 2021
11 Jan
2021 Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS